LYEL, US55083R2031

Lyell completes LYL273 transfer as analysts rate Lyell stock Moderate Buy

Published on 10/05/2026 at 21:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyell reported a USD 1.92 loss per share versus USD 1.94 consensus in Q2 2026. Nine analysts rate Lyell stock Moderate Buy at a USD 219.5 million market value.

LYEL, US55083R2031, Illustration mit AI erstellt.

Lyell Immunopharma (US55083R2031) completed the planned manufacturing transfer for LYL273 on September 10, 2026, while analysts maintained a Moderate Buy consensus for Lyell stock. The company is now advancing a Phase 1/2 study in metastatic colorectal cancer toward a recommended Phase 2 dose and an optimized safety plan.

LYL273 reaches the next trial stage

According to Lyell Immunopharma on September 10, 2026, the transfer moved LYL273 production to the company's LyFE Manufacturing Center in Bothell, Washington, after review by the U.S. Food and Drug Administration. The updated process and analytical methods are intended to improve manufacturing performance and increase capacity.

The company said additional LYL273 clinical data and an End-of-Phase 1 meeting with the FDA are expected in 2027, according to Lyell Immunopharma. The timing places manufacturing execution and trial dosing at the center of the next development milestone.

Second-quarter loss remains material

MarketBeat reported that Lyell posted a loss of USD 1.92 per share in the second quarter of 2026, compared with a consensus loss of USD 1.94 per share. The USD 0.02 per-share difference was favorable to consensus, while reported revenue was USD 0.00 million for the same period.

The quarterly result shows the company's development-stage profile: operating progress depends on clinical and manufacturing milestones rather than commercial sales. Lyell's lead programs remain focused on engineered T-cell therapies for hematologic malignancies and solid tumors, according to the company's September 10 release.

Analysts see a wide valuation spread

MarketBeat said nine analysts covered Lyell with six Buy ratings, one Strong Buy, one Hold and one Sell, producing a Moderate Buy consensus and an average 12-month target of USD 40.86. The rating mix contrasts with the company's USD 1.92 quarterly loss per share and underscores the market's dependence on future clinical execution.

On October 5, 2026, Lyell was trading at USD 8.96 on Nasdaq at 2:59 p.m. ET. Its market capitalization was USD 219.5 million, and the 52-week range was USD 8.69 to USD 45.00.

Clinical execution sets the next milestone

For investors, the key measurable milestones are the continued LYL273 dose escalation, the recommended Phase 2 dose and the additional clinical data expected in 2027. The September 10 manufacturing transfer strengthens the operational foundation for that work, but the second-quarter figures show that the company remains dependent on development progress rather than revenue generation.